- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS).
This study is looking at a new way to give eye injections for several common eye conditions that cause blurry vision. It's testing a pre-filled syringe of a drug called aflibercept to see how easy and safe it is to use. The aim is to make treatment simpler for patients.
Latvia - RecruitingPHASE2, PHASE3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
This study is looking for better treatments for a common eye condition called wet macular degeneration. Researchers want to see if a new medicine, tiespectus, works as well as an existing treatment, aflibercept. It's for people recently diagnosed with this condition.
For: Macular Degeneration · Age-Related Macular Degeneration · Choroidal NeovascularizationUnited States · Argentina · Australia - AuthorisedPhase II and Phase III (Integrated)
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
This study is looking at a new eye treatment, EYE201, for a serious eye condition called wet age-related macular degeneration (wet AMD). It compares EYE201 to an existing treatment, aflibercept, to see which is better at improving vision over one year.
For: Neovascular age-related macular degeneration (NVAMD)Spain · Poland · Estonia - Ongoing, recruitingPhase III and phase IV (Integrated)
Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)
This study looks at a new way to use an existing medicine, aflibercept 8mg, for an eye condition called wet age-related macular degeneration (wet AMD). It aims to see if longer times between injections are possible for people already treated with other medicines.
For: Neovascular age-related macular degenerationAustria